The role of the apolipoprotein E (APOE) ε4 allele as an effect modifier in lifestyle interventions to prevent cognitive impairment is still unclear.
D ementia and Alzheimer disease (AD) are complex conditions that likely result from interactions between genetic and environmental factors. 1 The apolipoproteinE(APOE) ε4 allele is the strongest known genetic risk factor for sporadic AD. 2 Most available studies 2, 3 have also linked APOE ε4 to an increased rate of late-life cognitive decline in individuals without dementia, although there is variability among the affected cognitive domains reported in different studies. 2, 3 Several modifiable risk factors for dementia have been identified in population-based studies. 3, 4 It is estimated that approximately one-third of all AD dementia cases worldwide could be attributable to low educational level, physical inactivity, obesity, hypertension, diabetes, smoking, and depression. 4 There is evidence that the APOE genotype interacts with modifiable risk factors, but variability in reported findings still precludes firm conclusions. 4, 5 One prevailing hypothesis is that APOE ε4 carriers are more susceptible to the detrimental effects of environmental risk factors. 5 It remains unclear whether ε4 carriers are more likely to benefit from preventive interventions or whether the ε4 allele counteracts potential intervention benefits.
APOE with its 3 isoforms (ε2, ε3, and ε4) has key roles in lipid transport and metabolism, both systemically and in the brain. 6, 7 The ε4 allele has been linked to cardiovascular and neurologic conditions, particularly AD. 6, 7 The connections between the ε4 allele and AD pathophysiologic findings seem to involve a variety of amyloid-dependent (eg, related to amyloid-β production, aggregation, and clearance) and amyloidindependent (eg, effects on tau phosphorylation and neurofibrillary tangle formation, neuroinflammation, oxidative stress, synaptic plasticity and dendritic spine integrity, brain lipid metabolism, and blood-brain barrier permeability) mechanisms. 6, 7 APOE ε4 carriers have brain structural and developmental features (eg, lower cortical gray matter volume in regions particularly affected by AD) that, together with functional features (eg, deficient neuronal maintenance and repair), increase vulnerability to neuropathologic changes and subsequent late-life cognitive decline. 5, 7 Previous randomized clinical trials (RCTs) that aimed to prevent cognitive impairment or dementia have yielded mainly negative results, 3 with some positive effects on cognition reported in smaller and/or shorter RCTs of physical activity and/or cognitive training. [8] [9] [10] [11] [12] [13] The effect of the APOE genotype on response to intervention was investigated in some of these RCTs. Beneficial effects among APOE ε4 carriers were reported in patients with mild cognitive impairment treated with donepezil hydrochloride 14 or galantamine hydrobromide, 15 in an RCT of eicosapentaenoic acid and docosahexaenoic acid, in an RCT of docosahexaenoic acid supplementation, 16, 17 and in a small 1-year weight loss RCT in elderly patients with obesity and mild cognitive impairment. 18 Some benefits for APOE ε4 carriers and noncarriers were observed in a trial of Mediterranean dietbased interventions, 19 whereas better effects among APOE ε4 noncarriers were found in a short physical activity RCT. 20 No effects of the APOE genotype on intervention response were found in trials of nonsteroidal anti-inflammatory drugs, 21 statins, 22 gingko biloba, 23 vitamin E, 14 or vitamin B 12
supplementation.
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The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was, to our knowledge, the first large, longer-term RCT to report beneficial effects on cognition for a 2-year multidomain lifestyle intervention in 1260 older at-risk individuals from the general population. 25 Herein, we report prespecified analyses of intervention effects on primary and secondary cognitive outcomes by APOE ε4 allele (carriers vs noncarriers).
Methods

Study Participants
The FINGER trial protocol, 26 
Randomization
From September 7, 2009, through November 24, 2011, a total of 2654 individuals were screened for eligibility, and 1260 were randomized 1:1 to the intensive multidomain intervention or regular health advice (ie, control) group. Computergenerated allocation was performed in blocks of 4 (2 persons randomly allocated to each group) at each site. Outcome assessors were masked to allocation and not involved in the intervention. Group allocation was not actively disclosed to participants, and they were advised not to discuss the intervention during testing sessions. Data analysis was performed from August 1, 2015, to March 31, 2016.
Intervention
The control group received regular health advice. Both groups met the study nurse at screening, baseline, and 6, 12, and 24 months (for blood tests and blood pressure, weight, body mass index, and hip and waist circumference measurements) and the study physician at screening and 24 months (for medical history and physical examination). At baseline, the study nurse gave both groups oral and written information and advice on healthy diet and physical, cognitive, and social activities beneficial for vascular risk management and disability prevention. Blood test results were mailed to all participants, together with general written information about the significance of measurements and advice to contact a primary health care practitioner if needed. The intervention group additionally received 4 intervention components. 26 The nutritional intervention was based on 
APOE Assessment
Genomic DNA was extracted from venous blood samples with Chemagic MSM1 (PerkinElmer) using magnetic beads. APOE genotyping was determined by polymerase chain reaction using TaqMan genotyping assays (Applied Biosystems) for 2 single-nucleotide polymorphisms (rs429358 and rs7412) and an allelic discrimination method on the Applied Biosystems 7500 platform.
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Statistical Analysis
Because of the small number of participants with the APOE ε4ε4 genotype (40 individuals, 16 in the control group and 24 in intervention group), participants were categorized as carriers of at least 1 ε4 allele vs noncarriers. For baseline comparisons between the intervention and control groups by APOE ε4 carrier status, the t test and χ 2 test were used as appropriate. Zero-skewness log transformation was applied to skewed NTB components. The z scores for tests at each time point were standardized to the baseline mean and SD. The NTB total score and domain scores for executive functioning, processing speed, and memory were obtained by calculating the mean of the individual NTB component z scores. The minimum number of necessary NTB components was set to 8 of 14 for calculating the NTB total score, 3 of 5 for executive functioning, 2 of 3 for processing speed, and 3 of 6 for memory. Because data included repeated measurements from the same individuals, longitudinal analyses had to take into account within-person and between-person variability over time. Mixed effects regression models (xtmixed command in Stata [StataCorp] ) with maximum likelihood estimation were thus used to analyze change in cognitive scores as a function of randomization group, time, APOE genotype (ε4 allele carriers vs noncarriers), and their interactions (group × time, group × APOE, time × APOE, and group × time × APOE). Following guidelines for subgroup analyses in clinical trials, 40 we report the coefficient (95% CI) for the group × time × APOE interaction as the main result (ie, estimated difference in intervention effects between ε4 carriers and noncarriers per year). We also present the effect estimates (95% CI) within each APOE group using the lincom postestimation command after xtmixed in Stata. Analyses were conducted according to the predefined primary efficacy analysis based on the modified intentionto-treat (mITT) population, including all randomized participants with at least 1 postbaseline observation (APOE genotype data available for 1109 of 1190 participants). Sensitivity analyses were conducted in the ITT population (all randomized participants; APOE genotype data available for 1175 of 1260 participants) and all randomized participants who completed all cognitive evaluations (APOE genotype data available for 1020 of 1094 participants). Level of significance was set to P < .05 in all analyses, and Stata software, version 14 (StataCorp), was used. No other significant differences in participants' baseline characteristics were found by availability of APOE data.
Results
Compared with participants without
In the mITT population, the number of APOE ε4 carriers was 173 (31.3%) in the intervention group and 189 (33.9%) in the control group (P = .34). Comparisons of population characteristics between the intervention and control groups among ε4 carriers and noncarriers are given in Table 1 . Among ε4 carriers, the intervention group had higher baseline diastolic blood pressure (81.08 vs 79.01 mm Hg, P = .048) and lower baseline memory performance (−0.07 vs 0.08, P = .04) compared with the control group (Table 1) . Intervention and control groups were not significantly different among ε4 noncarriers.
As expected, APOE ε4 carriers had higher baseline total and low-density lipoprotein cholesterol levels compared with noncarriers (Table 1) . No significant differences were found in baseline cognitive performance between ε4 carriers and noncarriers. However, memory performance at month 24 was significantly lower among ε4 carriers (0.27 vs 0.40, P = .02) ( Table 1) . Table 2 gives the estimated mean 2-year cognitive change in the intervention and control groups by APOE ε4 carrier status and annual differences between groups (primary analysis, mITT population). Intervention effects (randomization group × time × APOE interaction) did not significantly differ between ε4 carriers and noncarriers for any cognitive domain. Within-group findings by ε4 carrier status indicated that the annual difference between intervention and control groups was significant among ε4 carriers for NTB total score (estimate, 0.037; 95% CI, 0.001 to 0.073; P = .045) and abbreviated memory (estimate, 0.070; 95% CI, 0.006 to 0.135; P = .03) but not among noncarriers (estimates, 0.014 [95% CI, −0.011 to 0.039; P = .28] for NTB total score and 0.022 [95% CI, −0.023 to 0.066; P = .34] for abbreviated memory) ( Table 2) .
Sensitivity analyses found results similar to the main analyses (eTable 1 in the Supplement). Population characteristics for sensitivity analyses are given in eTable 2 in the Supplement.
Given the complexity of the models, further analyses were conducted to assess the best-fitting model by performing like- a Data are presented as mean (SD) unless otherwise specified.
b P value for differences between intervention and control groups among APOE ε4 carriers.
c P value for differences between intervention and control groups among APOE ε4 noncarriers.
d P value for differences between all APOE ε4 carriers and noncarriers.
lihood ratio tests and comparing the Bayesian Information Criterion for the full model with alternative models that excluded nonsignificant interaction terms (eTable 3 in the Supplement). Detailed results of the best-fitting model for each cognitive outcome are given in eTable 4 in the Supplement. The randomization group × time interaction was similar to previously reported intervention effects. 25 The time × APOE interaction was significant for NTB total score and memory, indicating less overall improvement (intervention and control groups together) among ε4 carriers compared with noncarriers (eTable 4 in the Supplement).
Discussion
Results from the 2-year FINGER trial did not show significant differences between APOE ε4 carriers and noncarriers (test of interaction) regarding the previously reported positive intervention effects on cognition. 25 However, within-group findings by APOE ε4 status showed beneficial intervention effects, especially among APOE ε4 carriers for NTB total score and abbreviated memory score, including more complex memory tests. Baseline performance in these cognitive domains was not different between intervention and control or carrier and noncarrier groups. The APOE ε4 allele is a key genetic risk factor for cognitive decline, AD, and dementia. 2, 5 One of the main concerns regarding dementia prevention strategies is whether genetically susceptible individuals can still benefit from preventive lifestyle interventions. Thus, the current findings have positive practical implications because the APOE ε4 allele did not seem to hinder the intervention benefits. Subgroup analyses in clinical trials are challenging. 40 Current reporting guidelines have emphasized between-group comparisons (ie, tests of interaction) as a more appropriate approach in assessing potential heterogeneity of intervention effects. 40 Guidelines have also cautioned against claims of heterogeneity based on only within-group results, which should not be overinterpreted. 40 Interpreting subgroup analyses in trials can be difficult for several reasons, including that statistical power for detecting significant interactions may be limited, dividing the trial population into smaller subgroups may also limit power and lead to nonsignificant within-group findings when the overall intervention effect is significant, and multiple subgroup analyses can increase the probability of false-positive findings. Thus, given the nonsignificant tests of interaction, the promising within-group findings cannot be considered as definitive evidence that the FINGER intervention was significantly more effective among APOE ε4 carriers. However, the lack of significant interactions should be interpreted cautiously because they may result from statistical power limitations, especially if effect sizes are relatively small. Despite the relatively large cohort and higher prevalence of the APOE ε4 allele in Finland compared with other European countries, 41 the sample size may still have limitations concerning interac- tions. In addition, the FINGER trial included several prespecified subgroup analyses besides APOE. 26 Findings reported here for 5 different cognitive outcomes were not adjusted for multiple testing because interactions were not significant. Further studies are needed to clarify whether APOE ε4 carriers may benefit more from lifestyle interventions. In the FINGER trial, overall improvement in NTB total score and memory was less pronounced among ε4 carriers compared with noncarriers (intervention and control groups together). The extended 7-year FINGER follow-up will provide additional data for investigating whether the multidomain lifestyle intervention is effective for preventing dementia, whether this effect is modified by APOE genotype, and whether the cognitive change pattern observed among ε4 carriers persists for a longer period.
Strengths and Limitations
The main strengths of this study are the large sample size, longer duration than what is most common in previous dementia prevention trials, thorough randomization and masking, detailed outcome assessments, and choice of target population. The FINGER participants were at-risk older individuals from the general population without dementia or substantial cognitive impairment (cognitive performance <0.5 SD below the mean level for the cognitively normal Finnish population).
27
The multimodal lifestyle intervention thus started early, before the occurrence of significant clinical impairment. This early start date may be particularly important for APOE ε4 carriers, who have increased susceptibility to detrimental effects of unhealthy lifestyle factors through a variety of mechanisms. [5] [6] [7] The multidomain intervention targeted multiple modifiable risk factors simultaneously, thus potentially covering several of these mechanisms.
This study has some limitations. Despite the relatively large cohort, there may be statistical power limitations for tests of interaction. The exact mechanisms of the within-group effects for APOE ε4 carriers could not be determined. Findings may not necessarily apply to individuals who already have substantial cognitive impairment because they were excluded from the trial.
Conclusions
Results from the FINGER trial suggest that healthy lifestyle changes could be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia. Whether such benefits are more pronounced in APOE ε4 carriers compared with noncarriers should be further investigated. The findings also emphasize the importance of early prevention strategies that target multiple modifiable risk factors simultaneously. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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Scores on the NTB total score and memory, executive functioning and processing speed domain scores are estimated mean values (standard errors) of z scores of the cognitive tests included in each cognitive outcome with higher scores indicating better performance. A positive value of the estimate of differences between intervention and control groups indicates the effect is in favor of the intervention group. BIC = -2*log-likelihood + log(number of observations)*(number of estimated parameters)
The best fitting mixed effects regression model (lowest BIC, bold font) was determined by performing likelihood-ratio tests and comparing the full model with alternative models excluding non-significant interaction terms.
* p value from likelihood ratio test comparing each alternative model with the full model.
All analyses were conducted in the main population (mITT). All tested models included the main effects of randomization group, time, and APOE, as well as the intervention effect (randomization group x time interaction). The best fitting mixed effects regression model is based on the lowest Bayesian Information Criterion (BIC) shown in Table S3 . N.A. -not applicable.
